Search Results

Amneal Pharmaceuticals, Inc. announced that it has entered into a settlement agreement with Actavis Laboratories FL, Inc. and Actavis Pharma Inc. (collectively, “Actavis”) resolving patent litigation related to Rytary® (carbidopa-levodopa).

Orexo AB today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC’s (Actavis) combined petition for panel rehearing and rehearing en banc in the case regarding Orexo’s Zubsolv US patent 8,940,330.

Bausch Health Companies Inc. and Progenics Pharmaceuticals, announced that the U.S. District Court of New Jersey upheld the validity and determined Actavis’ infringement of a patent protecting RELISTOR® tablets, expiring March 2031.

Orexo AB announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that Actavis’s generic Zubsolv products infringe Orexo’s U.S. patent No. 8,940,330

The litigation has been pending in the U.S. District Court for the District of Delaware and resulted from Actavis’s submission of an ANDA to the FDA seeking approval to market a generic version of Zohydro ER.

Under the agreement, Neos has granted Actavis the right to manufacture and market its generic version of Adzenys XR-ODT under the Actavis ANDA beginning on September 1, 2025, or earlier under certain circumstances.

Orexo AB (publ.), the fully integrated specialty pharmaceutical company, with strong long-term patent protection (no. 8,940,330) for its key product, Zubsolv® in the US, until September 2032, announces that the US District Court for the District of Delaware has declared that Actavis does not infringes Zubsolv´s short-term US patent no. 8,454,996 (“996"),

Under the Settlement Agreement, United Therapeutics granted to Actavis a license to manufacture and commercialize the generic version of Orenitram described in its ANDA filing in the United States beginning on June 15, 2027.

James Hindman, a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis

Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo’s long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016.